Intracellular inclusions are a unifying feature of polyglutamine (polyQ) neurodegenerative diseases, yet each polyQ disease displays a unique pattern of neuronal degeneration. This implies that the protein context of expanded polyQ plays an important role in establishing selective neurotoxicity. Here, in studies of the spinocerebellar ataxia type 3 disease protein ataxin-3, we demonstrate that the protein sequence surrounding polyQ specifies the constituents of nuclear inclusions (NI) formed by the disease protein. The nuclear proteins cAMP response element-binding protein-binding protein (CBP) and Mastermind-like-1 strongly colocalize only to NI formed by full-length ataxin-3, whereas the splicing factor SC35 colocalizes only to NI formed by a polyQcontaining, carboxyl-terminal fragment of ataxin-3. These differences in NI formation reflect specific protein interactions normally undertaken by ataxin-3, as both normal and mutant full-length ataxin-3 co-immunoprecipitate with CBP and sediment on density gradients as macromolecular complexes. Moreover, normal ataxin-3 represses cAMP response element-binding protein-mediated transcription, indicating a functional consequence of ataxin-3 interactions with CBP. Finally, we show that mutant ataxin-3 forms insoluble intranuclear complexes, or microaggregates, before NI can be detected, implying a precursor-product relationship. These results suggest that protein context-dependent recruitment of nuclear proteins to intranuclear microaggregates, and subsequently to NI, may contribute to selective neurotoxicity in polyQ diseases.
At least eight inherited neurodegenerative diseases are caused by expansion of a CAG trinucleotide repeat that encodes polyglutamine (polyQ) 1 in the disease protein (1) . Although the precise mechanism of neurotoxicity remains unknown, growing evidence suggests that polyQ diseases share certain pathogenic features. Protein misfolding, in particular, is thought to play a central role in most, if not all, polyQ diseases (2, 3). As a group, these diseases are characterized by abnormal accumulation or aggregation of the disease protein in neurons. In many polyQ diseases, these abnormal protein accumulations occur primarily in the nucleus and are known as nuclear inclusions (NI) (4, 5) .
However, despite their shared features, polyQ diseases are clinically and pathologically distinct. Only certain brain regions and neuronal populations degenerate in each disease, differing from one disease to the next (e.g. striatal projection neurons in Huntington disease, motor neurons in Kennedy disease). This selective neurodegeneration occurs despite widespread expression of the various disease proteins, implying that the unique protein composition of each expanded polyQ protein plays an important role in specifying the details of pathogenesis. This view is supported by studies showing that expanded polyQ, if removed from its normal protein context, aggregates and displays cytotoxicity but does not fully replicate specific features of disease (6, 7) . In contrast, full-length disease protein has successfully been used in some transgenic animals to model certain disease-specific features and may be more selectively neurotoxic than isolated polyQ fragments (8 -10) .
A unifying feature among polyQ diseases is the formation of intracellular inclusions in the cytoplasm, the nucleus (NI), or both. NI are found in most polyQ diseases, occurring in different brain regions depending upon the disease. Although NI may not be directly toxic structures (11) (12) (13) (14) , they likely represent biologic markers of the underlying pathogenic process and thus provide clues to pathogenesis (15) . Irrespective of the role of NI in disease, nuclear localization of the mutant polyQ protein is essential for the pathogenesis of at least some polyQ diseases (11, 12, 16) . Thus, there is considerable interest in identifying aberrant interactions between polyQ disease proteins and resident nuclear proteins. Transcription factors and cofactors represent one important class of nuclear proteins, many of which contain glutamine-rich or polyQ domains that may form aberrant intermolecular interactions with expanded polyQ. Several such proteins are now known to interact with specific polyQ disease proteins or be recruited to NI, and recent studies in cellular and animal models suggest that transcriptional dysregulation contributes to pathogenesis (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . One prominent example is the transcriptional coactivator, cAMP response element-binding protein (CREB)-binding protein or CBP (18 -20, 25) . CBP serves as a coactivator for many diverse transcription factors (27); hence, its sequestration in NI could have far-reaching consequences for affected neurons. In cellular models, recruitment of CBP to inclusions correlates with decreased transcription of a CBP-dependent reporter gene and polyQ toxicity can be mitigated by overexpressing CBP (20, 25) .
Here we address the role of protein context in polyQ disease, focusing on how the protein composition surrounding polyQ influences inclusion formation and recruitment of resident nuclear proteins. For these studies, we use as a model the polyQ disease protein in spinocerebellar ataxia type 3/Machado Joseph disease (SCA3/MJD). The most common dominantly inherited ataxia, SCA3/MJD is characterized by degeneration in the basal ganglia, brainstem, and cerebellum (28) . The SCA3/ MJD disease protein, ataxin-3, is the smallest identified polyQ disease protein. It is found in the cytoplasm and/or the nucleus of diverse cell types, and its function is unknown (28 -31) . The glutamine repeat of ataxin-3, which lies near the carboxyl terminus, is normally less than 42 repeats and becomes expanded in disease to 60 repeats or greater. In disease brain, mutant ataxin-3 accumulates in NI in several brainstem neuronal populations (32, 33) .
In studies comparing the intranuclear behavior of full-length and truncated ataxin-3, we demonstrate that protein composition plays a significant role in specifying the constituent proteins of NI. We also provide evidence that these differences in NI formation reflect specific protein-protein interactions normally undertaken by full-length ataxin-3, including with CBP. Further studies of the interaction of CBP with ataxin-3 show, unexpectedly, that this interaction occurs independent of the polyQ domain of CBP, implying that recruitment to NI is not mediated primarily by intermolecular polyQ-polyQ interactions. Finally, we address an important and controversial issue in the field: the relationship between intranuclear aggregation and NI formation. We demonstrate that the intranuclear formation of insoluble complexes, or microaggregates, of mutant ataxin-3 precedes the appearance of NI, suggesting a precursor-product relationship between the biochemical process of aggregation and the cellular process of inclusion formation.
MATERIALS AND METHODS
Plasmid Constructs-The ataxin-3 expression constructs pcDNA3-hemagglutinin (HA)-Q27, pcDNA3-HA-Q78, pcDNA3-myc-ataxin-3 (Q28), and pcDNA3-myc-ataxin-3 (Q84) were described previously (32, 34, 35) . Plasmids pFlag-ataxin-3 (Q28) and pFlag-ataxin-3 (Q84) were constructed by digesting myc-ataxin3 (Q28) and myc-ataxin-3 (Q84), respectively, with BamHI and cloning into pFLAG-CMV-2 (Sigma). All plasmid constructs were verified by restriction enzyme digest analysis and partial sequencing. Expression vectors pcDNA1-Flag-ataxin-1 (Q30) and pcDNA1-Flag-ataxin-1 (Q82) were generously provided by Dr. Huda Y. Zoghbi (Baylor College of Medicine, Houston, TX). pFLAG-CMV-2-MAML1-expressing vector was described previously (36) . pcDNA3.1-myc-CBP wild type and pcDNA3.1-myc-CBP with deletion of 19 glutamines and surrounding glutamine-rich region constructs were generously provided by Dr. David E. Housmon (Massachusetts Institute of Technology, Cambridge, MA). Rous sarcoma virus promoter expression vector containing the wild-type CREB was generously provided by Dr. Curt Sigmund (University of Iowa, Iowa City, IA). pCMX-PML and Gal4-tkLuc were kindly provided by Dr. Ronald M. Evans (Salk Institute for Biological Studies, La Jolla, CA). pCRE-Luc, pRL-TK, Gal4-Luc, and Gal4-CBP were generously provided by Dr. Kenneth H. Fischbeck (National Institutes of Health, Bethesda, MD).
Immunofluorescence and Immunohistochemistry-Methods for cell culture, transfection, and immunofluorescence have been described previously (32, 34, 35) . Epitope-tagged ataxin-3 constructs were detected with anti-myc polyclonal antibody (1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA) and anti-HA monoclonal antibody (12CA5, 1:500) (Roche Molecular Biochemicals). Ataxin-1 was detected with polyclonal anti-octapeptide (Flag) antibody (1:500) (Zymed Laboratories Inc., South San Francisco, CA). CBP was detected with monoclonal CBP antibody (C1, 1:100) and PML with monoclonal PML antibody (1:50) (all from Santa Cruz Biotechnology). SC-35 was detected with monoclonal SC-35 antibody (1:1000) (Sigma), and YT-521B with monoclonal anti-YT-521B antibody (kindly provided by Dr. Stefan Stamm, Max Planck Institute of Biochemistry, Martinsried, Germany). The nucleolus was detected with anti-fibrillarin antibody (kindly provided by Dr. Joseph Kraft, Yale University School of Medicine, New Haven, CT).
Methods to quantitate aggregates have been described previously (34, 35) . Aggregates were scored as cytoplasmic or nuclear aggregates based on 4,6-diamidino-2-phenylindole (DAPI) staining of nuclei. Aggregates falling within the range of DAPI staining were designated nuclear, whereas aggregates abutting or clearly outside the range of DAPI were designated cytoplasmic.
Confocal Microscopy and Triple Immunofluorescence-Samples were scanned with a Zeiss LSM 510 laser scanning confocal microscope using a 63ϫ plan-Apochromat oil objective. For triple immunofluorescence staining, fluorescein, rhodamine, or Cy5 dye was excited by laser light at a 488-, 543-, or 633-nm wavelength, respectively. Each fluorophore was scanned independently using the multitracking function of the LSM 510 unit. In triple staining, goat polyclonal PML antibody (N-19, 1:500) (Santa Cruz Biotechnology) was used to detect PML. For secondary antibodies (all from Jackson Immunoresearch Laboratories Inc., West Grove, PA), donkey anti-rabbit fluorescein (1:1,000) was used to label polyQ proteins, donkey anti-mouse rhodamine (1:1000) for SC-35, and donkey anti-goat Cy5 (1:1,000) for PML.
Co-immunoprecipitation-HeLa cells were replated into 100-mm dishes the day before transfection with the indicated expression vectors. Forty-eight hours after transfection, cells were washed twice with icecold buffer (50 mM Tris, 150 mM NaCl, pH 7.4), then solubilized in nondenaturing radioimmune precipitation assay lysis buffer (1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM Tris, 150 mM NaCl, pH 7.4) supplemented with 200 mM phenylmethylsulfonyl fluoride, 230 M leupeptin, and 5 M pepstatin A. Lysates were clarified by centrifugation at maximum speed in a tabletop centrifuge, and 300-l samples of supernatant (containing equal amounts of protein) were rotated overnight at 4°C with the indicated antibody or corresponding preimmune/nonimmune serum and 50 l of a 50% slurry of protein A-agarose (Santa Cruz Biotechnology). Immunoprecipitates were collected by centrifugation, and the protein A-agarose beads were washed four times with 700 l of lysis buffer. Agarose beads were then mixed with SDS-gel sample buffer, incubated 15 min at room temperature, and spun down briefly. Eluted samples were resolved by SDS-PAGE and transferred for immunoblot analysis as described previously (34) . Electrophoretically separated proteins were transferred to polyvinylidene difluoride membranes, blocked 1 h in blocking solution (5% nonfat powdered milk, 0.1% Tween 20 in Tris-buffered saline), and incubated 2 h with antibody specific for the expected co-precipitated protein.
Ataxin-3 was detected with monoclonal ataxin-3 antibody 1H9 (1:2,000; kindly provided by Y. Trottier, Strasbourg, France), polyclonal myc antibody (1:1,000), or monoclonal Flag antibody (M2) (1:1,000; Sigma). CBP, PML, and Mastermind-like-1 protein (MAML1) were detected with polyclonal CBP antibody (A22) (1:5,000; Santa Cruz Biotechnology), monoclonal PML antibody (1:1,000), and monoclonal Flag antibody (M2).
Cellular Fractionation and Velocity Sedimentation Analysis-At the specified times after transfection, HeLa cells expressing myc-ataxin-3 (Q28) or myc-ataxin-3 (Q84) were separated into cytoplasmic and nuclear fractions as described previously (31, 37) . For sucrose gradient analysis, 400 -500 l of nondenatured cell lysate was loaded on 5-30% sucrose gradients (total gradient volume, 13 ml) generated in 50 mM Tris, pH 7.8, 0.5 M NaCl, 0.75 mM benzamidine, 0.1 mM phenylmethylsulfonyl fluoride, and centrifuged at 4°C in a Beckman Vti 65.1 vertical rotor for 2 h at 50,000 rpm (38) . After centrifugation, 14 fractions (0.9 ml each) were collected starting from the top, and analyzed by SDS-PAGE and immunoblot. Simultaneous analysis of specific marker proteins from parallel gradients or of total cellular proteins from the test gradients (assessed by Coomassie Blue staining of SDS-polyacrylamide gels on which fraction were analyzed) showed consistent and reproducible velocity sedimentation from experiment to experiment. The ataxin-3 was detected with polyclonal myc antibody. Histone was detected with monoclonal histone antibody (1:200; Roche Molecular Biochemicals). NFB42 was detected with polyclonal NFB42 antibody (1: 2,000; kindly provided by Dr. Randall Pittman, University of Pennsylvania, Philadelphia, PA). 20 S proteasome core was detected with polyclonal 20 S proteasome core antibody (1:5,000; AFFINITI, Exeter, United Kingdom).
Luciferase Assays-HeLa cells in 24-well dishes were transiently transfected using LipofectAMINE Plus as recommended by the manufacturer (Life Technologies, Inc.). Each well was transfected with a constant amount of DNA containing firefly reporter plasmids pCRELuc (25 ng), Renilla reporter plasmids pRL-TK (2.5 ng), pCREB (100 ng) with 100 ng of empty vector (pFlag-CMV-2), encoding pFlagataxin-3 (Q28) or pFlag-ataxin-3 (Q84) to test CREB-dependent transcriptional activation. We also tested Gal-4-CBP-mediated transcription by using Gal4-Luc (25 ng), pRL-TK (2.5 ng), Gal-4-CBP (100 ng) with 100 ng of empty vector (pFlag-CMV-2), pFlag-ataxin-3 (Q28), or pFlag-ataxin-3 (Q84). Forty-eight hours after transfection, cells were lysed and assayed for luciferase activity using a Dual-Luciferase reporter assay system (Promega, Madison, WI) with an analytical luminescence laboratory Monolight 2010 luminometer. In all experiments, firefly luciferase activity was normalized to Renilla luciferase activity. Statistical analysis was performed using the paired t test, with p Ͻ 0.05 considered statistically significant.
RESULTS

Inclusion Heterogeneity: Differential Localization of Resident Nuclear Proteins to NI Formed by Full-length and Truncated
PolyQ Protein-We recently reported that CBP was recruited to NI formed by mutant ataxin-3 (20) . Recruitment of CBP and many other nuclear proteins to NI may be mediated, in part, by direct interactions between expanded polyQ and glutaminerich domains within these nuclear proteins (17, 18, 25, 39 ). Thus, we tested whether CBP could also be recruited to NI formed by a truncated ataxin-3 fragment consisting of just the COOH-terminal polyQ domain (HA-Q78). To test this, we transfected HeLa cells with full-length or truncated ataxin-3 and then performed immunofluorescence staining. When visualized by standard epifluorescence (Fig. 1A) , CBP strongly colocalized to NI formed by full-length mutant ataxin-3 but was barely detectable in NI formed by truncated ataxin-3. NI formed by a second, unrelated polyQ disease protein, the SCA1 disease protein ataxin-1, also showed surprisingly weak colocalization of CBP. Confocal microscopy ( Fig. 1B) confirmed this differential recruitment of CBP to NI; CBP colocalized nearly quantitatively to NI formed by full-length ataxin-3, but only poorly to NI formed by truncated ataxin-3 and weakly to NI formed by full-length ataxin-1 (and even then, only into a small subset of NI formed by ataxin-1). Identical results were found in differentiated PC12 neural cells; full-length ataxin-3 showed nearly quantitative recruitment of CBP, whereas truncated ataxin-3 and full-length ataxin-1 did not (data not shown). Thus, the differential localization of CBP to NI appears to depend on the nature of the aggregating disease protein rather than on the cell type.
This differential recruitment of proteins to NI presumably reflects differences in the protein composition surrounding expanded polyQ. To further address this, we examined the relationship of NI to various subnuclear domains, using antibodies specific for particular resident nuclear proteins. The mRNA splicing factor SC-35, which normally exists in a speckled nuclear pattern (40) , colocalized only to NI formed by truncated ataxin-3 and not by full-length ataxin-3 or ataxin-1 (Fig. 2) . In contrast, the promyelocytic leukemia antigen (PML), a major protein component of PML nuclear bodies (41) , colocalized to all types of NI, whether formed by full-length ataxin-3, truncated ataxin-3 or full-length ataxin-1. However, the pattern of PML colocalization differed among NI. Whereas PML distributed uniformly throughout NI formed by full-length ataxin-3, it became concentrated along the periphery of NI formed by ataxin-1.
The specific localization of SC-35 to NI formed by truncated ataxin-3 prompted us to test whether another protein implicated in mRNA splicing, YT-521B, also colocalized to NI. YT-521B normally resides in specific subnuclear domains and may participate in mRNA splicing and the assembly of transcription centers (42, 43) . Though we confirmed that YT-521B does localize to subnuclear "dots," it did not colocalize to NI formed by truncated or full-length polyQ proteins (data not shown). Thus, putative mRNA splicing-associated nuclear proteins do not, as a rule, become sequestered in NI. Moreover, the abundant nucleolar protein fibrillarin failed to localize to any type of NI, whether formed by truncated or full-length mutant ataxin-3 (data not shown).
Both Normal and Mutant Ataxin-3 Interact with CBP and PML-The above results indicate that NI formed by different polyQ proteins differ with respect to colocalizing nuclear proteins. In particular, the strong colocalization of CBP and PML to NI formed by full-length ataxin-3 suggested that ataxin-3 might normally interact with these two nuclear proteins. To test this, we performed co-immunoprecipitation studies of ataxin-3 with CBP and PML. Lysates of HeLa cells co-expressing normal or mutant ataxin-3 together with CBP or PML were immunoprecipitated with anti-CBP or anti-PML antibody. Coprecipitated ataxin-3 was then visualized by immunoblot analysis with monoclonal ataxin-3 or anti-myc antibody (Fig. 3 , A and top panel of C, respectively). Both normal and expanded ataxin-3 formed complexes that coprecipitated with CBP and PML. These results were confirmed by the reverse coimmunoprecipitations in which ataxin-3 antibody was used to immunoprecipitate complexes, followed by immunoblot analysis with anti-CBP or anti-PML antibody (Fig. 3, B and bottom panel of C, respectively). Again, both CBP and PML co-precipitated with normal or expanded ataxin-3. Because these immunoprecipitations are not quantitative, we cannot determine the precise amount of the cellular pool of ataxin-3 complexed with CBP or PML. However, we estimate that it is less than 20%, with no appreciable difference between normal and mutant ataxin-3. It is important to recognize that only a fraction of the cellular pool of ataxin-3 localizes to the nucleus, and it is only this fraction that is likely to form complexes with CBP or PML.
To assess whether these protein-protein interactions were specific to ataxin-3 or were more generally true of polyQ proteins, we tested whether an unrelated polyQ disease protein, the SCA1 protein ataxin-1, also coprecipitated with CBP and PML. Ataxin-1 is a nuclear protein with no sequence similarity to ataxin-3 other than a shared polyQ tract (28, 44) . In contrast to ataxin-3, normal and mutant ataxin-1 did not coprecipitate with CBP or PML (Fig. 3, D and E) . Thus, CBP and PML interactions do not seem to be generally true for all nuclearexpressed polyQ disease proteins.
Ataxin-3/CBP Interaction Does Not Require the Glutaminerich Domain of CBP-Studies have suggested that intermolecular polyQ-polyQ interactions contribute to aggregation and recruitment in polyQ diseases (17, 18, 25, 39) . The colocalization of CBP to huntingtin inclusions, for example, requires the presence of the COOH-terminal glutamine-rich domain of CBP (18, 25) . To determine whether the same was true for CBP interactions with ataxin-3, we coexpressed wild type CBP or CBP deleted of its glutamine-rich domain (CBP-QD) together with expanded ataxin-3, and then assayed for colocalization to NI. Unexpectedly, CBP-QD still colocalized to NI formed by full-length ataxin-3 (Fig. 4A) . Thus, the glutamine-rich domain of CBP is not required for recruitment of CBP to ataxin-3 inclusions. Co-immunoprecipitation studies were consistent with this finding, as both normal and expanded ataxin-3 still coprecipitated with CBP lacking the glutamine-rich domain (Fig. 4, B and C) . In contrast, soluble COOH-terminal ataxin-3 fragment with a normal or expanded polyQ domain did not coprecipitate with full-length CBP (data not shown). Taken together, these results imply that interactions between ataxin-3 and CBP are not mediated primarily via intermolecular polyQ-polyQ interactions, but via other domains in both proteins.
Normal Ataxin 3 Represses CREB-mediated Transcription-CBP functions as a general coactivator for many transcription factors, including CREB (27, 45). Thus, interactions between ataxin-3 and CBP might be expected to alter CREB-mediated transcription specifically or CBP-dependent gene expression more generally. To test this, we performed transient transcriptional reporter gene assays to determine the effect of ataxin-3 expression on both CREB-and CBP-mediated transcription. Employing a CREB response element-luciferase reporter construct (pCRE-Luc) (Fig. 5A) , we found that normal ataxin-3 significantly repressed CREB-dependent transcription by approximately half. Interestingly, we did not observe significant repression of CREB-dependent transcriptional activity by expanded ataxin-3. To assess ataxin-3 effects on general transcriptional activation by CBP, we employed a GAL4-CBP fusion protein and a GAL4 promoter-luciferase reporter gene in transient assays. In contrast to the results with CREB-mediated expression, ataxin-3 expression had no effect on CBP-dependent transcription, with either normal or expanded polyQ (Fig. 5B) . These results suggest that interactions between nonpathogenic ataxin-3 and CBP specifically alter CREB-mediated gene expression without generally inhibiting the transcriptional coactivator function of CBP.
MAML1 Differentially Localizes to NI Formed by Full-length Ataxin-3-MAML1
is a human homologue of Mastermind, a transcriptional co-activator for Notch signaling in Drosophila (36) . Normal MAML1 protein localizes to PML nuclear bodies (36) and, thus, might be expected to colocalize with ataxin-3 in NI. To test this, we transfected differentiating PC12 neural cells with full-length or truncated mutant ataxin-3, then performed immunofluorescence staining. As shown in Fig. 6A , MAML1 colocalized strongly with most NI (ϳ80%) formed by full-length ataxin-3, but not to NI formed by truncated ataxin-3. This preferential localization resembled our results with CBP; thus, we tested whether ataxin-3 also interacts with MAML1 by co-immunoprecipitation. Unlike CBP and PML, MAML1 did not coprecipitate with normal or expanded ataxin-3 (Fig. 6B) . Thus, the strong recruitment of specific nuclear proteins to NI appears not to be limited to proteins that interact, directly or indirectly, with the mutant polyQ protein.
The results nevertheless do suggest that the recruitment of proteins into NI is highly dependent upon the protein sequence surrounding polyQ.
Velocity Sedimentation Analysis of Ataxin-3 Reveals a Macromolecular Complex-
The preceding results suggested to us that ataxin-3 might normally exist within a macromolecular complex. To address this, we performed velocity sedimentation analysis with sucrose density gradient centrifugation. Normal or mutant ataxin-3 was expressed in transfected cells, and lysates were then centrifuged through 5-30% sucrose gradients followed by fractionation and immunoblot analysis for ataxin-3. Both normal and expanded ataxin-3 consistently sedimented broadly across the gradient (Fig. 7, A and B) , in contrast to control proteins, which displayed narrow, smaller sedimentation profiles (Fig. 7C) . Although most ataxin-3 migrated near the top of the gradient with sedimentation coefficients less than 6 S, a significant proportion sedimented as higher molecular weight species of between 8 and 20 S, indicative of large macromolecular complexes. On sucrose gradients, ataxin-3 sedimenting as higher molecular weight complexes preferentially comprised the lower band of a closely spaced ataxin-3 doublet. We routinely see this doublet with both normal and expanded ataxin-3 from transfected cells. The molecular basis for this doublet, and for the preferential association of the lower isoform with macromolecular complexes, requires further investigation.
Intranuclear Aggregation Precedes Inclusion Formation by Mutant Ataxin-3-It is now widely believed that protein misfolding is central to polyQ pathogenesis and that, for several polyQ diseases, nuclear localization of the disease protein is important in the disease process (2, 3, 11, 12, 16) . Nevertheless, the role of NI in pathogenesis is controversial, and a causal or temporal relationship has not yet been established between intranuclear protein misfolding and aggregation, which can be viewed as purely biochemical process, and inclusion formation, which can be viewed as a cell biological process. Because in our cellular models mutant ataxin-3 forms easily visualized NI in a time-dependent manner, we were in a position to address this issue. Specifically we sought to determine whether full-length, mutant ataxin-3 formed biochemically detectable, insoluble complexes (i.e. aggregates) that temporally preceded the formation of NI.
Previously we showed that an expanded polyQ-containing fragment of ataxin-3 forms high molecular weight, insoluble complexes that remain in the stack of denaturing SDS-polyacrylamide gels. To determine whether full-length, expanded ataxin-3 also formed SDS-insoluble aggregates, we expressed myc-ataxin-3 (Q28) or myc-ataxin-3 (Q84) in HeLa cells, harvested cells 48 h after transfection, fractionated the lysates into cytoplasmic and nuclear pools, and subjected these fractions to SDS-PAGE and immunoblot analysis. On denaturing gels, a portion of the cellular pool of mutant ataxin-3 formed SDSinsoluble aggregates that remained in the stack or at the top of the separating gel (top panel of Fig. 8A ). These insoluble aggregates were observed almost entirely in the nuclear fraction, FIG. 5 . Normal ataxin 3 represses CREB-mediated transcription. A, HeLa cells were transfected with a CREB response element reporter gene construct alone, together with CREB or with CREB plus normal or expanded ataxin-3. 24 h later, cells were analyzed for CREB-mediated transcription (luciferase activity). B, CBP-dependent transcription was also measured using a GAL4 reporter construct cotransfected with constructs encoding GAL4-CBP fusion protein or GAL4-CBP plus normal or expanded ataxin-3. Results are the mean Ϯ S.D. from three independent experiments performed in duplicate, normalized for transfection efficiency. *, p Ͻ 0.001, CREB plus normal ataxin-3 versus CREB plus control vector. 
FIG. 7.
Velocity sedimentation analysis of normal and mutant ataxin-3. Clarified lysates from HeLa cells expressing normal or expanded, myc-tagged ataxin-3 (A and B, respectively) were centrifuged on 5-30% linear sucrose density gradients. Equal samples from the collected fractions were subjected to SDS-polyacrylamide gel electrophoresis and analyzed by immunoblot with anti-myc antibody. Normal and mutant ataxin-3 both exist as a closely spaced doublet (arrow) that sediments broadly across the gradient, with a small but significant subpopulation reproducibly sedimenting at higher S values indicative of large macromolecular complexes (fractions [7] [8] [9] [10] [11] [12] [13] [14] . Note that the lower isoform of the doublet preferentially sediments at higher S values. An SDS-resistant putative dimer of ataxin-3 (arrowheads) is also observed for normal and mutant ataxin-3. Panel C shows two marker proteins analyzed on parallel gradients, the neural-specific F box protein NFB42, which sediments at 2-4 S, and a 20 S proteasome core subunit. Fractions are numbered from top to bottom of each gradient. even though at least as much ataxin-3 is present in the cytoplasm in these transfected cells. Insoluble aggregates were never observed with normal ataxin-3 protein, whether in the nucleus or cytoplasm. Successful subcellular fractionation of lysates into cytoplasmic and nuclear fractions was confirmed by probing immunoblots with anti-histone antibody (bottom panel of Fig. 8A ).
Next we determined the temporal relationship between aggregate formation, as detected by SDS-insoluble complexes on gel electrophoresis, and NI formation, as detected by immunofluorescence microscopy. In general, NI of full-length mutant ataxin-3 are not present in appreciable numbers until 3 days after transfection (Fig. 8C) . In contrast, high molecular weight, SDS-insoluble aggregates of ataxin-3 appear as soon as 24 h after transfection and remain at fairly constant levels for several days (Fig. 8B) . During this same time course on parallel samples of transfected cells, no NI and only a single cytoplasmic inclusion were observed at 24 h. Only at 72 h was there a significant percentage of cells containing cytoplasmic or nuclear inclusions (Fig. 8C) . Thus, the formation of macroscopic inclusions in this cellular model is preceded by the formation of high molecular weight, insoluble complexes or microaggregates. This temporal relationship suggests a precursor product relationship between microaggregate formation and the development of nuclear inclusions.
DISCUSSION
In the studies described here, we have addressed the role of protein composition in polyQ-mediated aggregation and inclusion formation. This is an important issue because the distinct pattern of neuronal degeneration in each polyQ disease implies that the amino acid sequence surrounding expanded polyQ contributes to selective neuronal vulnerability. Using ataxin-3 as a model protein, we have presented evidence here that: 1) the surrounding protein composition of expanded polyQ helps to specify the molecular constituents of NI; 2) differences in NI formation reflect, in part, normal interactions undertaken by polyQ disease proteins in the nucleus; 3) for ataxin-3, these normal interactions include the formation of soluble complexes with two transcriptional coactivators, CBP and PML; and 4) in transfected cells, the appearance of macroscopic NI is preceded by the appearance of insoluble micro-aggregates of mutant ataxin-3, implying a precursor-product relationship between intranuclear aggregation and subsequent NI formation.
Our principal finding is the evidence for clear differences in the molecular composition of NI formed by full-length versus truncated forms of a polyQ protein. This represents the first demonstration that NI differ depending upon the protein context of the expanded polyQ domain. Whereas the nuclear proteins CBP and MAML1 specifically localized to NI formed by full-length ataxin-3, the splicing factor SC35 only localized to NI formed by a polyQ fragment of ataxin-3. Moreover, NI formed by two unrelated disease proteins, ataxin-3 and ataxin-1, also differed from each other; CBP strongly colocalized only to NI formed by ataxin-3. Even for PML, a protein that in our hands localizes to all NI, the details of colocalization differed. For example, PML was present uniformly throughout NI formed by ataxin-3, but was confined to the periphery of NI formed by ataxin-1. PML is a major component of the PML nuclear body, a protein-based subnuclear structure associated with the nuclear matrix (46) . Within PML nuclear bodies, PML protein is immobile, indicating that it may play a structural role (47) . In contrast, CBP moves relatively rapidly into and out of PML nuclear bodies, becoming enriched in these structures only in certain cell types. Its selective accumulation in PML nuclear bodies in certain cells may be determined in part by interactions with other proteins, including PML (47) . Based on our results and the work of others (34, 48, 49) , we suspect that all NI form within, or in close association with, PML nuclear bodies. In contrast, based on the marked differences in CBP colocalization to NI, we propose that CBP becomes selectively recruited or retained within NI because of specific interactions with full-length ataxin-3.
The protein components of NI probably include vestiges of protein-protein interactions undertaken by the polyQ disease protein before aggregation occurs. Because of the selective and robust sequestration of CBP and PML within NI formed by ataxin-3, we suspected that this polyQ protein may normally interact with these two nuclear proteins. Indeed, co-immuno- precipitation studies confirmed that ataxin-3 forms soluble complexes with CBP and PML. Importantly, these interactions were observed for both normal and expanded ataxin-3, suggesting that the nonpathogenic function of ataxin-3 includes interactions with these two transcriptional coactivators. These results are consistent with the view that specific protein interactions normally undertaken by polyQ disease proteins help to determine the molecular constituents of NI. Our results with MAML1, however, show that such interactions are not the only determinant of NI composition because MAML1 still localized to NI despite not co-immunoprecipitating with ataxin-3.
What do differences in NI composition tell us about pathogenesis? NI likely represent a biological marker of protein misfolding and aggregation, and thus provide insight into aberrant protein-protein interactions that may contribute to pathogenesis. Based on our results, we suggest that truncated and full-length ataxin-3 interact with different, yet overlapping, sets of nuclear proteins. Some interactions presumably occur only with full-length protein and are required to elicit the full disease phenotype. We speculate that only full-length protein will be capable of causing the selective neuronal degeneration seen in SCA3/MJD. Testing this prediction will require comparative studies in transgenic animals that express fulllength versus truncated ataxin-3. In addition, it will be important to extend these studies to human disease brain.
The "polyQ toxic fragment" hypothesis posits that proteolysis generates polyQ-containing fragments of disease protein that are especially prone to misfold, aggregate, and cause cytotoxicity (4, 50) . Consistent with this hypothesis, studies in transgenic mice and transfected cells have shown that an ataxin-3 fragment is more cytotoxic and prone to form aggregates than the full-length protein (7, 32) . However, despite in vivo evidence supporting cleavage in certain diseases (notably HD and DRPLA; Refs. 51 and 52), there is no direct evidence that proteolysis is essential to pathogenesis in SCA3/MJD or any other polyQ disease. Moreover, our results show that intact ataxin-3 is fully capable of forming both insoluble aggregates (detected on gels) and NI (detected by immunofluorescence). Thus, proteolysis of ataxin-3 need not be invoked as a critical driving force in its aggregation.
Recent evidence suggests that transcriptional dysregulation contributes to the pathogenesis of polyQ diseases (19 -25) . CBP has received particular attention because it localizes to NI in several diseases and normally plays a vital role in neuronal survival (18, 19, 20, 25) . Several researchers have proposed a "CBP sequestration" model of pathogenesis in which NI functionally deplete the cell of this critically important transcriptional coactivator (19, 20, 25) . In the current study, CBP nearly quantitatively localized to NI formed by ataxin-3, suggesting that very little CBP remains available for transcriptional activity in NI-containing cells. In contrast, little if any CBP colocalized to NI formed by an ataxin-3 fragment. This result has two implications for the CBP sequestration model. First, if CBP sequestration is relevant to SCA3/MJD, it is unlikely to be mediated by a proteolytic fragment. Second, the mechanism of recruitment cannot be simple homotypic interactions between the polyQ domains of ataxin-3 and CBP. The fact that CBP deleted of its glutamine-rich domain still becomes sequestered in NI further supports this second point. In other words, expanded polyQ alone is not sufficient to recruit CBP, nor is the polyQ domain of CBP necessary for recruitment by ataxin-3. These findings argue against a general model of polyQ pathogenesis in which intermolecular polyQ interactions cause CBP sequestration. To the extent CBP recruitment occurs in disease, it is more complicated than simple polyQ-polyQ interactions.
Our immunoprecipitation results showing interactions between normal ataxin-3 and CBP prompted us to look for ataxin-3 mediated changes in CBP function using transcriptional reporter assays. Our results suggest that interactions between nonpathogenic ataxin-3 and CBP alter CREB-mediated gene expression specifically without generally inhibiting CBP's transcriptional coactivator function. A significant negative finding is our failure to detect an inhibition of CBP-dependent transcription by mutant ataxin-3. The results argue that soluble mutant ataxin-3 does not globally repress CBP-dependent transcription, even though some ataxin-3 is in the appropriate subcellular compartment (the nucleus) to act on CBP. We stress that this does not rule out the possibility that aggregated ataxin-3, in the form of NI, functionally depletes CBP from the cell.
Our studies do not address whether ataxin-3 interactions with CBP or PML occur directly or indirectly. Both CBP and PML form numerous multiprotein complexes and bind many nuclear proteins, including each other (27). Thus, ataxin-3 interactions with CBP and PML may be indirect, occurring as part of a larger protein complex and mediated through other proteins. Our velocity sedimentation analyses, showing that a fraction of the cellular pool of ataxin-3 resides in large macromolecular complexes, are consistent with this possibility. Currently, little is known about the normal protein partners for ataxin-3. The only proteins known to bind ataxin-3 directly are the DNA repair proteins hHR23A and hHR23B, shown by yeast two-hybrid analysis (53) . Interestingly, hHR23A also interacts with CBP and, through this interaction, may promote crosstalk between DNA repair and p53 pathways (54) . Further biochemical studies will be required to determine whether ataxin-3 binds CBP, PML, and hHR23A in the same or different multiprotein complexes and whether ataxin-3 modulates functional interactions between hHR23A and CBP.
Finally we provide evidence that mutant ataxin-3 forms SDS-insoluble, high molecular weight aggregates in the nucleus even before inclusions are visible. This finding is important for several reasons. First, it represents direct evidence of aggregation by the full protein; hence, proteolytic cleavage is not required for aggregation. Second, the aggregates form primarily in the nucleus, suggesting that intranuclear ataxin-3 is particularly prone to aggregate. The relationship between this preferential nuclear aggregation and a previously described nuclear-specific conformation of ataxin-3 (31) now needs to be explored. Third, the fact that we observe SDS-insoluble complexes before inclusions argues for a precursor-product relationship between the biochemical process of aggregation and the cellular process of inclusion formation. This point may seem obvious, but the origin and role of inclusions in polyQ disease is far from clear. Indeed, the presence of NI does not always correlate with toxicity and, in some studies, has even been interpreted as cytoprotective (11, 12) . Our results suggest that, upstream of inclusion formation, mutant ataxin-3 forms insoluble complexes, or microaggregates, that serve as the seed for NI formation. The process of NI formation is likely to be more complex than the aggregation preceding it and to be influenced by other cellular factors. NI may prove to be the nuclear equivalent of the cytoplasmic aggresome, which represents a coalescence of aggregated protein that is actively concentrated by cytoskeletally driven processes (55) .
